177Lu-Ofatumumab

N/A

Report date: 2025/11/03 14:46:29

Base Information

Drug Name177Lu-Ofatumumab

Drug Alias Name[177Lu]Lu-ofatumumab177Lu-CHX-A"-ofatumumab

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionAnti-CD20

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesWashington University School Of Medicine

China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of Medicine

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A